Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Narges Baluch

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
BMC Cancer|September 1, 2019
Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphaneReza Bayat Mokhtari, Narges Baluch, Evgeniya Morgatskaya, et al.
Cancers|July 24, 2021
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance ImmunotherapyReza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, et al.
Biomedicines|January 28, 2026
HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision ManagementFaezeh Shekari, Reza Bayat Mokhtari, Razieh Salahandish, et al.
Oncotarget|July 28, 2021
Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Oncotarget|September 12, 2022
Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Biomolecules|September 27, 2025
A Comprehensive Oncological Biomarker Framework Guiding Precision MedicineReza Bayat Mokhtari, Manpreet Sambi, Faezeh Shekari, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
BMC Cancer|September 1, 2019
Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphaneReza Bayat Mokhtari, Narges Baluch, Evgeniya Morgatskaya, et al.
Cancers|July 24, 2021
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance ImmunotherapyReza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, et al.
Biomedicines|January 28, 2026
HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision ManagementFaezeh Shekari, Reza Bayat Mokhtari, Razieh Salahandish, et al.
Oncotarget|July 28, 2021
Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Oncotarget|September 12, 2022
Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosisReza Bayat Mokhtari, Bessi Qorri, Narges Baluch, et al.
Biomolecules|September 27, 2025
A Comprehensive Oncological Biomarker Framework Guiding Precision MedicineReza Bayat Mokhtari, Manpreet Sambi, Faezeh Shekari, et al.
Pageof 2